Abstract
Neuritic plaques composed mainly of amyloid β-protein (Aβ) in the brain are an early and invariant neuropathological feature of Alzheimers disease (AD). The current search for anti-AD drugs is mainly focused on modification of the process of Aβ deposition in the brain. In this article, the recent development of the molecules that inhibit the formation of β-amyloid fibrils (fAβ), as well as destabilize preformed fAβ is reviewed. Recently, various compounds such as curcumin, nicotine and wine-related polyphenols have been reported to inhibit the formation, extension of fAβ, as well as destabilize preformed fAβ at pH 7.5 at 37°C in vitro. In cell culture experiments, destabilized fAβ were suggested to be less toxic than intact fAβ. In transgenic mice model study, some coumpounds such as curcumin and nicotine have also been reported to reduce plaque burden in vivo. Although the mechanisms by which these compounds inhibit fAβ formation from Aβ, and destabilize preformed fAβ are still unclear, they could be key molecules for the development of preventives and therapeutics for AD.
Keywords: Alzheimer's disease, β-amyloid fibrils, organic compounds, thioflavin T, electron microscopy
Current Pharmaceutical Design
Title: The Development of Preventives and Therapeutics for Alzheimers Disease that Inhibit the Formation of β-Amyloid Fibrils (fAβ), as Well as Destabilize Preformed fAβ
Volume: 12 Issue: 33
Author(s): Kenjiro Ono, Hironobu Naiki and Masahito Yamada
Affiliation:
Keywords: Alzheimer's disease, β-amyloid fibrils, organic compounds, thioflavin T, electron microscopy
Abstract: Neuritic plaques composed mainly of amyloid β-protein (Aβ) in the brain are an early and invariant neuropathological feature of Alzheimers disease (AD). The current search for anti-AD drugs is mainly focused on modification of the process of Aβ deposition in the brain. In this article, the recent development of the molecules that inhibit the formation of β-amyloid fibrils (fAβ), as well as destabilize preformed fAβ is reviewed. Recently, various compounds such as curcumin, nicotine and wine-related polyphenols have been reported to inhibit the formation, extension of fAβ, as well as destabilize preformed fAβ at pH 7.5 at 37°C in vitro. In cell culture experiments, destabilized fAβ were suggested to be less toxic than intact fAβ. In transgenic mice model study, some coumpounds such as curcumin and nicotine have also been reported to reduce plaque burden in vivo. Although the mechanisms by which these compounds inhibit fAβ formation from Aβ, and destabilize preformed fAβ are still unclear, they could be key molecules for the development of preventives and therapeutics for AD.
Export Options
About this article
Cite this article as:
Ono Kenjiro, Naiki Hironobu and Yamada Masahito, The Development of Preventives and Therapeutics for Alzheimers Disease that Inhibit the Formation of β-Amyloid Fibrils (fAβ), as Well as Destabilize Preformed fAβ, Current Pharmaceutical Design 2006; 12 (33) . https://dx.doi.org/10.2174/138161206778793010
DOI https://dx.doi.org/10.2174/138161206778793010 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Patents on the Use of Antioxidant Agents in Food
Recent Patents on Food, Nutrition & Agriculture Management of Obesity in Patients with Type 2 Diabetes Mellitus
Current Diabetes Reviews Fibrosis, Enzymatic and Non-Enzymatic Cross-Links in Hypertensive Heart Disease
Cardiovascular & Hematological Disorders-Drug Targets Actions of Rho-Kinase Inhibitors in Cardiovascular Diseases
Current Enzyme Inhibition Reactive Oxygen Species in the Initiation of IL-4 Driven Autoimmunity as a Potential Therapeutic Target
Current Pharmaceutical Design Current Insights into the Role of HIF-1 in Cutaneous Wound Healing
Current Molecular Medicine Binding Interactions of Forskolin with Human Serum Albumin: Insights from In silico and Spectroscopic Studies
Current Chemical Biology A Systematic Review of Overweight, Obesity, and Type 2 Diabetes Among Asian American Subgroups
Current Diabetes Reviews Mitochondrial Therapeutics for Cardioprotection
Current Pharmaceutical Design Role of PI3 Kinase Gamma in Excitation-Contraction Coupling and Heart Disease
Cardiovascular & Hematological Disorders-Drug Targets Repetitive Transient Phosphodiesterase-3 Inhibition Eliminates Non-ischemic Cardiac Remodeling and Failure
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Novel Therapies for Schizophrenia: Understanding the Glutamatergic Synapse and Potential Targets for Altering N-methyl-D-aspartate Neurotransmission
Recent Patents on CNS Drug Discovery (Discontinued) The Development of Antibody-based Immunotherapy for Methamphetamine Abuse: Immunization, and Virus-Mediated Gene Transfer Approaches
Current Gene Therapy Phenotypes of Obstructive Sleep Apnea and Direct Targeted Therapy: A Literature Review
Current Respiratory Medicine Reviews Hypertension in Obstructive Sleep Apnoea
Vascular Disease Prevention (Discontinued) Plant Sterols and Stanols as Cholesterol-Lowering Ingredients in Functional Foods
Recent Patents on Food, Nutrition & Agriculture The Economic Costs for the Control of Cardiovascular Risk: An Overview
Current Pharmaceutical Design A Genome-wide Association Analysis in Four Populations Reveals Strong Genetic Heterogeneity For Birth Weight
Current Genomics Biological Abilities of Rice Bran-Derived Antioxidant Phytochemicals for Medical Therapy
Current Topics in Medicinal Chemistry Neuropharmacological Aspects of Crocus sativus L.: A Review of Preclinical Studies and Ongoing Clinical Research
CNS & Neurological Disorders - Drug Targets